biostudies-literatureDittmar RLThe Cancer Prevention Institute of TexasNIEHS NIH HHSNIEHSNCI NIH HHSNational Institutes of Health Translational Genomics and Precision Medicine in Cancer T32 Training ProgramCancer Prevention Research Institute of TexasNIHNIH NCI729-740https://www.ebi.ac.uk/biostudies/studies/S-EPMC8818322biostudies-literatureUnknown14(7)Early detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes; however, PDAC is usually diagnosed late. Therefore, blood-based minimally invasive biomarker assays for limited volume clinical samples are urgently needed. A novel miRNA profiling platform (Abcam Fireplex-Oncology Panel) was used to investigate the feasibility of developing early detection miRNA biomarkers with 20 μL plasma from a training set (58 stage II PDAC cases and 30 controls) and two validation sets (34 stage II PDAC cases and 25 controls; 44 stage II PDAC cases and 18 controls). miR-34a-5p [AUC = 0.77; 95% confidence interval (CI), 0.66-0.87], miR-130a-3p (AUC = 0.74; 95% CI, 0.63-0.84), and miR-222-3p (AUC = 0.70; 95% CI, 0.58-0.81) were identified as significantly differentially abuCancer prevention research (Philadelphia, Pa.)Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.PMC8818322U01 CA200466U01 CA2529651P42ES0327725RP170005U01CA200468CA125123U01 CA196403U01 CA200468T32 CA217789P30 ES0302855T32CA217789-03P30 CA125123U01CA196403U01 CA214263P50CA221707P50 CA221707RP1803921 U01 CA2142631P30ES030285Tai MCLongton GDeCapite CCoarfa CRajapakshe KLiu SParis PLSen SHuang YKirkwood KSMaitra AHurd MWBrand REDittmar RLKillary AMfalsePlasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.Early detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes; however, PDAC is usually diagnosed late. Therefore, blood-based minimally invasive biomarker assays for limited volume clinical samples are urgently needed. A novel miRNA profiling platform (Abcam Fireplex-Oncology Panel) was used to investigate the feasibility of developing early detection miRNA biomarkers with 20 μL plasma from a training set (58 stage II PDAC cases and 30 controls) and two validation sets (34 stage II PDAC cases and 25 controls; 44 stage II PDAC cases and 18 controls). miR-34a-5p [AUC = 0.77; 95% confidence interval (CI), 0.66-0.87], miR-130a-3p (AUC = 0.74; 95% CI, 0.63-0.84), and miR-222-3p (AUC = 0.70; 95% CI, 0.58-0.81) were identified as significantly differentially abu2021-01-01T00:00:00Z2021 Jul2026-05-31T20:54:43.615Z2025-04-06T11:13:34.788ZS-EPMC88183223389307110.1158/1940-6207.capr-20-030310.1158/1940-6207.CAPR-20-0303